a Journal of Postdoctoral Research and Postdoctoral Affairs.
    ISSN : 2328-9791
left right
Development and preclinical testing of a novel antimicrobial peptide to treat Pseudomonas aeruginosa-induced lung infections
Author(s) : Mangoni ML, Cappiello F, Casciaro B, Luca V, Chen C, Lin Q, Di PY
Address : Department of Biochemical Sciences, Sapienza University of Rome, Rome-Italy, Department of Environmental and Occupational Health, University of Pittsburgh, USA
Sapienza University of Rome, University of Pittsburgh

Background. Pseudomonas aeruginosa is the most predominant lung pathogen in patients with cystic fibrosis (CF). It is quite difficult to eradicate because of its acquired resistance to most available antibiotics and ability to form sessile communities or biofilms, in a protective extracellular matrix. Cationic antimicrobial peptides (AMPs) hold promise as future anti-infective agents.

Hypothesis and objectives. Our objective was to develop a short-sized AMP from frog skin, Esc(1-21) and/or its diastereomer containing two D-amino acids, for treatment of P. aeruginosa lung infections. To this aim: (i) an in-vitro analysis of the anti-pseudomonal, anti-inflammatory, wound healing properties of the two peptides, and (ii) preclinical testing to establish both the peptides' safety profiles and therapeutic dosages were performed.


home phone mail info@postdocjournal.com
twitter facebook social icon Social link You Tube sky
Click Here